Trial · NCT02613221
Adverse events43
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 43
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Panitumumab + TAS-102 | 9 | 55 | |
| other | Vertigo | Ear and labyrinth disorders | Panitumumab + TAS-102 | 3 | 55 | |
| other | Abdominal pain | Gastrointestinal disorders | Panitumumab + TAS-102 | 6 | 55 | |
| other | Diarrhoea | Gastrointestinal disorders | Panitumumab + TAS-102 | 17 | 55 | |
| other | Nausea | Gastrointestinal disorders | Panitumumab + TAS-102 | 23 | 55 | |
| other | Stomatitis | Gastrointestinal disorders | Panitumumab + TAS-102 | 39 | 55 | |
| other | Vomiting | Gastrointestinal disorders | Panitumumab + TAS-102 | 8 | 55 | |
| other | Fatigue | General disorders | Panitumumab + TAS-102 | 27 | 55 | |
| other | Malaise | General disorders | Panitumumab + TAS-102 | 10 | 55 | |
| other | Pyrexia | General disorders | Panitumumab + TAS-102 | 9 | 55 | |
| other | Blood bilirubin increased | Investigations | Panitumumab + TAS-102 | 4 | 55 | |
| other | Neutrophil count decreased | Investigations | Panitumumab + TAS-102 | 36 | 55 | |
| other | Platelet count decreased | Investigations | Panitumumab + TAS-102 | 13 | 55 | |
| other | White blood cell count decreased | Investigations | Panitumumab + TAS-102 | 7 | 55 | |
| other | Hypomagnesaemia | Metabolism and nutrition disorders | Panitumumab + TAS-102 | 12 | 55 | |
| other | Decreased appetite | Metabolism and nutrition disorders | Panitumumab + TAS-102 | 30 | 55 | |
| other | Proteinuria | Renal and urinary disorders | Panitumumab + TAS-102 | 3 | 55 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Panitumumab + TAS-102 | 4 | 55 | |
| other | Dermatitis acneiform | Skin and subcutaneous tissue disorders | Panitumumab + TAS-102 | 34 | 55 | |
| other | Palmar-plantar erythrodysaesthesia syndrome | Skin and subcutaneous tissue disorders | Panitumumab + TAS-102 | 14 | 55 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02613221/events